Atlas›Domain XII · Complementary, energy & biofield›Guide 057
Guide XII-057

Complex and clinical homeopathy

A 31 · L 60 · M 912 interventions in the Trinity explorer
Client cardCompare
[source: …] where a claim comes from[uncertain] not confirmed in a primary source[synthesis] the writer's reconstruction

1. Introduction

Version followed: complex (combination) and clinical homeopathy as described in German pharmacy and pharmaceutical-reference sources (apotheken.de, aponet.de, and the Govi-Verlag reference work Arzneimittel der komplementären Medizin), with Heel's own account of homotoxicology, and regulation as published by the FDA, MHRA, Health Canada, NHS England and NCCIH. The psychotherapist works alongside this method and does not practise, sell, prescribe or recommend homeopathic products. Sections 1–3 describe the method as its own sources publish it; section 4 is the psychotherapist's own work alongside it.

What it is. Homeopathy is a medical system developed in Germany more than 200 years ago, built on two principles as its practitioners hold them: "like cures like" (a substance that causes symptoms in a healthy person is used for similar symptoms in illness) and the "law of minimum dose" (the belief that more dilute preparations work better; many products are diluted so far that none of the starting substance may remain) [source: NCCIH]. Two departures from the single-remedy "classical" method are covered here:

  • Clinical homeopathy (German klinische Homöopathie): the remedy is chosen mainly by the affected organ or by the medical diagnosis (for example, a sinus or tonsil infection), rather than by the individual's whole symptom picture; it is less individualised and partly uses conventional diagnoses [source: apotheken.de, Renz-Polster].
  • Complex homeopathy (Komplexmittelhomöopathie): ready-made products containing several homeopathic single remedies in a fixed combination, often in different potencies, frequently marked "comp." on the label [source: apotheken.de; aponet.de]. Complexes are typically sold for an indication (e.g. bladder complaints) and products for the same indication vary widely in their components [source: Borchardt, in Reichling et al. 2001].
  • Homotoxicology (Heel): a system developed in 1948 by the physician and homeopath Hans-Heinrich Reckeweg, who founded the company Heel in Berlin in 1936 (later headquartered in Baden-Baden). The company describes the aim as using the body's own capacity to regulate itself, using natural medicines to activate its autoregulating mechanisms [source: Heel history page]. In the reference-work account, harmful substances called "homotoxins" are held to cause illness, the body responds by excreting or depositing them, and Heel's "antihomotoxic" combination products are presented as an extension of complex homeopathy [source: Borchardt 2001].

Core idea of change (as practitioners hold it). Change is attributed to the remedy's similarity to the symptom pattern (or, in complex and clinical approaches, to the indication) and, in homotoxicology, to stimulation of self-regulation and elimination of homotoxins. These are the system's own claims, attributed here. Evidence status (one line): Australia's NHMRC (2015) concluded there is "no reliable evidence that homeopathy is effective for any health condition" [source: NCCIH]; there is no scientific evidence that it can prevent or treat cancer [source: Cancer Research UK].

2. Framework

Complex and clinical homeopathy is a family of product-based approaches, not a staged treatment programme. The "framework" below describes how clients meet it, so the therapist can understand what the client is doing.

Routes by which a client meets it [source: apotheken.de; aponet.de; Cancer Research UK; Borchardt 2001]:

  • Self-selection of over-the-counter complexes for an indication (colds, sleep, nerves, bladder, joints). In Germany, pharmacies offer advice on choice and use; registered homeopathic products are sold without a stated indication, while products with specific indications in principle need marketing authorisation [source: aponet.de].
  • Consultation with a practitioner (in Germany, physicians or Heilpraktiker [uncertain: not verified]; elsewhere homeopaths, naturopaths, some physicians, vets). A first consultation typically covers health, lifestyle, diet, medical history, sleep and mood, and lasts about 45 minutes, with shorter follow-ups; UK fees are reported at around £30–£125 [source: Cancer Research UK].
  • Clinical selection by diagnosis or organ rather than full case-taking [source: apotheken.de]. Classical homeopathy, by contrast, uses detailed case-taking and repertorisation (comparing symptom patterns against remedy profiles) to choose a single remedy [source: apotheken.de; aponet.de].
  • Seller-designed combination systems: some sellers combine products with questionnaires and "sublingual testing" to pick a formula and tie formulas to conditions (described in a seller's own promotional article) [source: King, mpamedia].

Forms. Tablets, granules, powders, liquids, drops and creams [source: Cancer Research UK]; Heel also produced ampoule products ("Injeels") [source: Heel history page]. Routes other than oral or topical (eye, nasal, injection) are an FDA enforcement priority [source: FDA]. (No doses, potencies or administration are given in this guide.)

System concepts named for orientation only. Potency scales and "comp." labelling; "initial aggravation" (Erstverschlimmerung), the belief that symptoms may first worsen, which Heel's complexes were said to counter [source: Borchardt 2001]; Cancer Research UK notes some homeopaths warn "symptoms could get worse first" but that this is infrequent.

Regulation (one line each).

  • USA: "There are no FDA-approved products labeled as homeopathic"; FDA's December 2022 guidance sets risk-based enforcement priorities (injury reports, ingredients with safety concerns, non-oral/non-topical routes, claims for serious or life-threatening disease such as cancer, products marketed to children, pregnant women or the elderly, quality problems); FDA has issued more than 20 warning letters since 2020 [source: FDA homeopathic products page; FDA 2022 guidance]. The FTC (2016) holds OTC homeopathic health claims to the same evidence standard as other products [source: NCCIH].
  • UK: MHRA Simplified Registration allows no therapeutic indications; the National Rules Scheme allows claims for minor, self-limiting conditions "within the UK homeopathic tradition"; quality and safety, not efficacy, are assessed [source: MHRA]. NHS England (2017) lists homeopathy among items that should not routinely be prescribed in primary care [source: NHS England SPS review]. No single body regulates homeopaths; most belong to professional bodies such as Homeopathy UK or the Faculty of Homeopathy [source: Cancer Research UK].
  • Germany: under the medicines law, registered homeopathics carry no indication; for complexes with an indication, re-approval required each component to contribute positively to the claimed indication [source: Borchardt 2001; aponet.de].
  • Canada: nosodes are "not, and never have been, approved by Health Canada to be vaccine alternatives", and nosode labels must state they are neither a vaccine nor an alternative to vaccination (2019) [source: Health Canada].

3. Guiding principles

These principles shape the psychotherapist's own stance [synthesis unless tagged].

  • Never perform, sell, prescribe or recommend. You do not suggest, endorse, choose, or comment on doses of any remedy; questions about products go to the prescriber or pharmacist [source: FDA advice to consult doctor or pharmacist].
  • Curiosity without judgement. Ask routinely and neutrally; clients who expect disapproval stop disclosing.
  • Attribute, do not adjudicate. Describe homeopathic concepts as the system holds them; give evidence status in one line if asked, without ridicule.
  • Autonomy plus safety. Respect adult choices about complementary use; act on risk when it threatens conventional care, children or vulnerable adults.
  • Complementary, never instead. Health bodies advise not using homeopathy to replace proven care or vaccinations [source: NCCIH; Health Canada]; your concern is substitution and delay, not the product as such.
  • Coordinate with consent. Encourage clients to tell their doctor, cancer team or pharmacist [source: NCCIH; Cancer Research UK; NHS].
  • Medicines are not your remit. Never advise starting, stopping or changing a medicine or remedy; the NHS advises not stopping prescribed medicine without first talking to a doctor [source: NHS].
  • Stay in your lane on physical claims. No method here is presented as treating cancer or other physical disease.
  • No conflicts of interest. No product sales, referral fees or business relationships with sellers.
  • Work with the psychological function. Remedy use often carries meaning (control, hope, identity, distrust); that meaning is the therapeutic material.

4. Intervention inventory

All interventions below are the psychotherapist's own work alongside a client's use of complex or clinical homeopathy. Unless tagged otherwise, the procedures are [synthesis] built on the health-body advice cited. Example language is illustrative throughout.

4.1 Routine, non-judgemental inquiry and recording

  • Purpose / when: at intake and at reviews, and whenever the client mentions new physical symptoms, sleep or mood changes, or "natural" products. Health bodies ask people to tell professionals about complementary therapies they use [source: NHS; NCCIH].
  • Steps: (1) Ask an open, normalising question about all remedies, including over-the-counter combination products, "comp." products, drops, globules and anything recommended by a practitioner or pharmacy. (2) Record product names as the client gives them, who suggested them, what for, and whether the doctor or pharmacist knows. (3) Ask whether any conventional treatment, appointment or vaccination has been delayed or stopped in favour of it. (4) Do not comment on dose, potency or choice. (5) Revisit at reviews.
  • Example language (illustrative): "Many people use homeopathic or natural remedies alongside other care. Are you using any at the moment, including combination products from the pharmacy? I ask everyone, so I have the full picture."
  • Watch for: hesitancy or defensiveness (signals expected disapproval); products for serious conditions; injectable, eye or nasal products (FDA priority routes) [source: FDA]; use for a child. Working: the client volunteers updates without being asked.

4.2 Exploring meaning, hopes, expectations and explanatory model

  • Purpose / when: when remedy use seems significant to the client, or is tied to distrust of medicine, a chronic condition or an identity.
  • Steps: (1) Ask what drew them to it and what they hope it will do. (2) Explore their model of illness (e.g. "toxins", self-regulation, "treating the whole person") in their own words, attributing it rather than correcting it. (3) Explore functions: control, hope, being listened to (long consultations), distrust after a medical injury, family or cultural tradition, community. (4) Ask what it would mean if it did or did not help. (5) Reflect the underlying need and consider other ways it might be met.
  • Example language (illustrative): "What is it about this approach that feels right for you?" / "It sounds like the homeopath really listened, which hasn't always happened with your doctors."
  • Watch for: fixed beliefs that any conventional treatment is "suppressive" or toxic; hope invested in a single product for a serious illness; shame. Working: the client can talk about the remedy flexibly and name their wider goals.

4.3 Supporting informed, values-based decisions without coercion

  • Purpose / when: when the client is weighing homeopathy against, or alongside, conventional treatment, or asks what you think.
  • Steps: (1) Clarify the decision and the timeline. (2) Elicit values and priorities. (3) Help the client list questions for their doctor or pharmacist (effectiveness, interactions, what happens if treatment is delayed). (4) Where useful, point to public information from health bodies (e.g. NHS, NCCIH, Cancer Research UK) without prescribing a choice. (5) Summarise the client's own reasoning back. (6) Respect the decision; keep safety planning open. No published decision aid is specified here [uncertain: not verified].
  • Example language (illustrative): "I'm not the right person to advise on remedies, but I can help you think through what matters most and what you want to ask your doctor."
  • Watch for: pressure from family, sellers or the therapist's own views; decisions made under acute fear. Working: the client can describe the options and trade-offs in their own words.

4.4 Coordination with the client's doctor, pharmacist or treating team

  • Purpose / when: when products are used alongside prescribed medicines, during pregnancy, for a child, or with a serious illness. FDA advises talking to a doctor or pharmacist about which products are safe [source: FDA]; Cancer Research UK advises telling cancer doctors before using any homeopathic remedy [source: Cancer Research UK]; NCCIH advises bringing products to the health care provider, since some are not highly diluted and may cause side effects or interactions [source: NCCIH].
  • Steps: (1) Encourage the client to tell the prescriber or pharmacist and bring the product packaging. (2) Offer to help them prepare. (3) With written consent, share relevant information with the GP or team. (4) Record consent and the communication.
  • Example language (illustrative): "Would you be willing to show this to your pharmacist? Some products labelled homeopathic contain enough of an ingredient to matter alongside other medicines."
  • Watch for: refusal to involve the doctor because of anticipated criticism (explore it); the therapist being asked to judge interactions (decline, route to pharmacist).

4.5 Recognising and responding to substitution or delay of medical care

  • Purpose / when: if the client uses homeopathy instead of conventional treatment, delays investigation of symptoms, or stops prescribed medicine. FDA notes people may use unapproved products instead of effective treatment, delaying or stopping care; CRUK reports a concern that people might stop conventional treatment [source: FDA; Cancer Research UK]. NCCIH: "Don't use homeopathy to replace proven conventional care."
  • Steps: (1) Ask directly about stopped or delayed care. (2) Assess urgency (severe, unusual or persistent symptoms need medical assessment [source: aponet.de]). (3) Share concern clearly and respectfully. (4) Encourage, and offer to help arrange, medical review. (5) For a capacitous adult, respect the choice while keeping the door open and documenting. (6) If capacity is in doubt or risk is imminent, follow local emergency and safeguarding procedures.
  • Example language (illustrative): "I respect that this is your decision. I'm worried because these symptoms haven't been checked by a doctor. Could we think together about getting them looked at, alongside whatever else you choose?"
  • Watch for: red-flag symptoms; claims by a seller that a product treats cancer or serious disease (an FDA enforcement priority) [source: FDA]; rapid deterioration. Working: medical review is arranged and the alliance holds.

4.6 Children, vaccination, pregnancy and safeguarding

  • Purpose / when: when a parent uses products on a child, considers nosodes or "homeoprophylaxis" instead of vaccination, or the client is pregnant or breastfeeding. Health Canada warns that children given nosodes instead of vaccines risk serious, potentially fatal illness and that nosodes are not vaccine alternatives; NCCIH advises consulting a provider first for pregnancy, nursing or a child and following immunisation schedules [source: Health Canada; NCCIH]. In 2017 FDA warned that some homeopathic teething tablets contained excessive belladonna [source: NCCIH].
  • Steps: (1) Ask neutrally about remedies given to children and vaccination status where relevant to your role. (2) Encourage discussion with the child's doctor, health visitor or paediatrician. (3) Assess whether a child is being deprived of necessary medical care; if so, follow your local safeguarding procedures and consult your safeguarding lead. (4) For a pregnant client, encourage discussion with the midwife or obstetrician. (5) Include the child's assent and views where age-appropriate. (6) Document.
  • Example language (illustrative): "Health Canada and other bodies are clear that these products don't replace vaccines. Would you be willing to talk this through with your child's doctor?"
  • Watch for: a child with untreated serious symptoms; parental conflict over treatment; pressure from a practitioner to avoid vaccines.

4.7 Recognising product-safety concerns

  • Purpose / when: when a client reports new symptoms after starting a product, uses non-oral products, or buys from unregulated sources. Sources state: some products labelled homeopathic contain measurable amounts of active ingredients, some are made from known poisons or toxins, improper manufacturing can cause contamination or incorrect dilution [source: FDA]; some products have contained heavy metals [source: Cancer Research UK].
  • Steps: (1) Note the product name and source. (2) Encourage the client to stop guessing about cause and contact their doctor or pharmacist promptly (you do not advise stopping or continuing). (3) If symptoms are severe, direct to urgent care. (4) Inform the client of adverse-event reporting routes (see 4.11).
  • Example language (illustrative): "I can't tell whether the product is involved, but a pharmacist or doctor can. Could you call them today and take the packaging with you?"
  • Watch for: symptoms being reframed as "initial aggravation" so medical help is not sought; products bought online from overseas sellers.

4.8 Financial exploitation, seller systems and group pressure

  • Purpose / when: when the client spends heavily, is enrolled in a seller's testing-and-formula system, sells products to others, or feels pressured by a practitioner or community. Seller systems may combine questionnaires and "sublingual testing" to select proprietary formulas [source: King, mpamedia]; describe these as the seller does without endorsing them.
  • Steps: (1) Ask about costs and who benefits financially. (2) Explore the client's sense of choice versus obligation. (3) Look for multi-level-marketing recruitment, escalating purchases or isolation from other advice [synthesis]. (4) Support budgeting and boundary-setting. (5) Where consumer harm or misleading claims are suspected, note consumer and advertising reporting routes (4.11).
  • Example language (illustrative): "How much has this been costing each month, and how do you feel about that?"
  • Watch for: debt, secrecy from family, fear of leaving the group. Working: the client makes spending decisions freely.

4.9 Health anxiety and somatic symptom presentations

  • Purpose / when: when remedy-seeking is driven by persistent worry about illness, repeated checking, multiple practitioners, or medically unexplained symptoms. Use established psychological approaches (CBT for health anxiety, approaches for somatic symptom distress); see Domain II for full procedures [synthesis].
  • Steps: (1) Formulate the cycle (worry → checking or remedy-seeking → short-term relief → renewed worry). (2) Explore whether remedy use functions as reassurance-seeking or safety behaviour, without asking the client to stop any remedy (that is their and their prescriber's decision). (3) Apply the Domain II approach. (4) Coordinate with the GP to avoid fragmented care.
  • Example language (illustrative): "When you take a new product, what happens to the worry over the next few days?"
  • Watch for: escalating product use, new symptom focus, avoidance of medical review. Working: reduced preoccupation and more flexible coping.

4.10 Responding to requests for the therapist's opinion or recommendation

  • Purpose / when: when a client asks "Should I take this?", "Which one works?" or invites you to share a practitioner or product.
  • Steps: (1) Acknowledge the question. (2) State your role clearly: you do not recommend or advise on remedies or medicines. (3) If asked about evidence, give the one-line status neutrally [source: NCCIH]. (4) Redirect to pharmacist or doctor. (5) Return to the client's underlying concern. (6) Decline any product, referral or business relationship; manage conflicts of interest [synthesis; consult your professional ethics code].
  • Example language (illustrative): "That's a question for your pharmacist or doctor rather than me. What I can do is help you think about what you're hoping for."
  • Watch for: your own bias (enthusiasm or contempt) leaking into the session.

4.11 Reporting routes

  • Purpose / when: adverse effects, misleading health claims, products marketed as vaccine alternatives, child-safety concerns, or practitioner misconduct.
  • Steps (by jurisdiction):
    • USA: product problems to FDA via its "Report a Product Problem" route or 1-888-INFO-FDA [source: FDA]; deceptive advertising to the FTC [source: NCCIH, on FTC's 2016 policy; FTC route uncertain: not verified].
    • UK: products are regulated by the MHRA [source: MHRA]; adverse-reaction reporting via the MHRA Yellow Card scheme and advertising complaints to the Advertising Standards Authority [uncertain: not verified]; practitioner concerns to the professional body the practitioner belongs to (e.g. a PSA-accredited register) [source: NHS; Cancer Research UK].
    • Canada: Health Canada's online complaint form for non-compliant sale or advertising [source: Health Canada].
    • Germany: BfArM regulates medicinal products [source: Borchardt 2001]; reporting route details [uncertain: not verified].
    • Children: local safeguarding procedures in all jurisdictions.
  • Example language (illustrative): "If you think the product caused this, there's a national reporting system for that. Would you like help finding it?"
  • Watch for: clients' fear of "getting someone into trouble"; your own duty to act where a child is at risk.

4.12 Serious illness and psycho-oncology alongside

  • Purpose / when: a client with cancer or another serious illness using, or considering, homeopathy. Cancer Research UK states there is no evidence it can prevent or treat cancer and that it should not replace conventional treatment.
  • Steps: (1) Hold respectful conversations about alternatives without ridicule. (2) Encourage the client to tell the cancer team. (3) Support palliative-care referral where relevant. (4) Work with family conflict about treatment choices. (5) Support grief and regret if a client or family feels alternatives delayed care, without blame. Cross-refer 172 (integrative oncology) [synthesis].
  • Example language (illustrative): "It makes sense to want to try everything. Would it help to talk about how to tell your cancer team what you're using?"
  • Watch for: hope and fear driving rapid decisions; family splits; self-blame later.

5. Handling problems

The homeopathy sources do not address psychotherapy problems; all guidance below is [synthesis] unless tagged.

  • Client hides remedy use. Normalise and repeat the routine question at reviews; explain why you ask (whole picture, not judgement). Avoid evidence debates that make disclosure costly.
  • Client wants you to endorse or debunk. Decline both; state your role (4.10). If asked for evidence status, give the one line neutrally [source: NCCIH] and return to the client's goals.
  • Rupture after you voice concern. Acknowledge that it may have felt dismissive; separate concern for the client from views on the remedy; invite the client's reaction; repair before returning to safety issues.
  • Client refuses to involve the doctor. Explore the fear (criticism, past medical harm). Offer to help script the conversation. For a capacitous adult with no imminent risk, respect the choice and document; revisit later.
  • "Initial aggravation" used to explain worsening symptoms. The concept is part of the system [source: Borchardt 2001; Cancer Research UK]; do not argue it. Focus on safety: worsening symptoms should be checked by a doctor (4.7).
  • Remedy use as avoidance of psychological work (e.g. a "nerves" complex instead of addressing stressors). Explore function collaboratively, without asking the client to stop; set goals that do not depend on the remedy's success or failure.
  • Overwhelm when facing serious-illness decisions. Slow the pace, ground, narrow to the next single decision, and involve trusted supports and the treating team (4.3, 4.12).
  • Non-adherence to prescribed medicines in favour of remedies. Do not give medication advice; express concern, encourage urgent review with the prescriber, and document [source: NHS advice not to stop prescribed medicine without talking to a doctor].
  • Family conflict (one partner using remedies for the children, the other opposed). Hold a neutral stance on the remedy; centre the child's welfare and medical care; apply safeguarding procedures where deprivation of care is suspected (4.6).
  • Group or seller pressure (questionnaires, testing systems, recruitment to sell). Explore costs and freedom to leave (4.8).
  • Therapist's own beliefs. Whether sympathetic or sceptical, monitor for bias; take it to supervision. Never sell, recommend or take referral fees.
  • Grief and regret after choosing alternatives. Avoid hindsight blame; validate the hope that drove the choice; work with guilt and family recriminations (4.12).

Sources

← Previous · XII-056Classical homeopathyNext · XII-058 →Sensation method (Sankaran)